A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
NPS MedicineWise media release – bDMARDS September 2019 (002)
Discover more...
-
Australian Rheumatology Association and Arthritis Australia Statement regarding the use of glucosamine for the treatment of Osteoarthritis
Recent media reports have raised concern over the use of glucosamine in the treatment of osteoarthritis. These reports appear to be based on two unrelated...
-
UPDATED: Advice regarding Coronavirus (Covid-19) from the Australian Rheumatology Association
Due to the increasing number of infections in Australia from Coronavirus (Covid-19), we are aware of growing concerns raised by patients with chronic illnesses and...
-
A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
